Salvatore Siena

52PUBLICATIONS
277CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (52)

|Jul 01, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

|May 13, 2026
Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

|Jan 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

John H Strickler, Andrea Cercek, Salvatore Siena

|Sep 22, 2025
The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

Marco Avolio, Simonetta M Leto, Francesco Sassi

|Jan 15, 2025
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.

Salvatore Siena, Kanwal Raghav, Toshiki Masuishi

|Nov 27, 2024
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection.

Marco Macagno, Valeria Pessei, Noemi Congiusta

Pageof 9

Frequent Collaborators

28 joint publications

Paolo Bianchi

12 joint publications

Silvia Marsoni

11 joint publications

Federica Di Nicolantonio

11 joint publications

Alberto Bardelli